v3.25.4
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 10,209 $ 10,346
Marketable debt securities 464 513
Receivables 11,414 10,747
Inventories 2,690 2,557
Other current assets 4,613 5,617
Total Current assets 29,390 29,780
Property, plant and equipment 7,543 7,136
Goodwill 21,754 21,719
Other intangible assets 19,103 23,307
Deferred income taxes 5,378 4,236
Marketable debt securities 396 320
Other non-current assets 6,474 6,105
Total Assets 90,038 92,603
Current liabilities:    
Short-term debt obligations 2,261 2,046
Accounts payable 3,575 3,602
Other current liabilities 17,581 18,126
Total Current liabilities 23,417 23,774
Deferred income taxes 222 369
Long-term debt 42,850 47,603
Other non-current liabilities 5,043 4,469
Total Liabilities 71,533 76,215
Commitments and Contingencies (Note 20)
Bristol-Myers Squibb Company Shareholders’ Equity:    
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 2,510 in 2025 and 2,868 in 2024, liquidation value of $50 per share 0 0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2025 and 2024 292 292
Capital in excess of par value of stock 46,387 46,024
Accumulated other comprehensive loss (1,524) (1,238)
Retained earnings 16,896 14,912
Less cost of treasury stock — 887 million common shares in 2025 and 894 million common shares in 2024 (43,579) (43,655)
Total BMS Shareholders’ Equity 18,473 16,335
Noncontrolling interest 33 53
Total Equity 18,506 16,388
Total Liabilities and Equity $ 90,038 $ 92,603
Preferred stock, shares outstanding (in shares) 2,510 2,868
Preferred stock, shares issued (in shares) 2,510 2,868